Related Experiment Video
Updated: Jun 1, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Alzheimer's disease: rapid and slow progression
Craig J Thalhauser1, Natalia L Komarova
1Department of Mathematics, University of California Irvine, Irvine, CA 92697, USA.
Journal of the Royal Society, Interface
|June 10, 2011
Summary
Alzheimer's disease (AD) progression varies significantly between patients. This study identified two distinct progression patterns, suggesting different underlying mechanisms and impacting treatment development.
Area of Science:
- Neurology
- Gerontology
- Biostatistics
Background:
- Alzheimer's disease (AD) exhibits considerable variability in its progression among individuals.
- This heterogeneity complicates the identification of effective disease-delaying treatments.
- Understanding AD progression is crucial for developing targeted therapeutic strategies.
Purpose of the Study:
- To quantitatively analyze the variability in Alzheimer's disease progression using the Functional Assessment Staging (FAST) scale.
- To identify distinct patterns or subtypes of AD progression.
- To investigate the implications of these patterns for understanding AD pathophysiology and treatment.
Main Methods:
- Statistical analysis of Functional Assessment Staging (FAST) stage durations.
- Utilized a dataset comprising 648 patients with Alzheimer's disease.
- Applied methods to identify distinct distributions of progression times within each FAST stage.
Main Results:
- Identified two distinct patterns of Alzheimer's disease progression based on FAST stage durations.
- These patterns are characterized by significantly different mean progression rates, with variations up to two years between stages.
- Demonstrated that rapid progression in one FAST stage predicts rapid progression in subsequent stages.
Conclusions:
- Alzheimer's disease progression may follow at least two distinct pathophysiological pathways.
- These pathways result in different average rates of cognitive and functional decline.
- Findings support the need for personalized approaches in AD management and treatment development.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.